Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men

Beibei Lu, Raphael P Viscidi, Yougui Wu, Ji Hyun Lee, Alan G. Nyitray, Luisa L. Villa, Eduardo Lazcano-Ponce, Roberto J. Carvalho Da Silva, Maria Luiza Baggio, Manuel Quiterio, Jorge Salmeron, Danelle C. Smith, Martha E. Abrahamsen, Mary R. Papenfuss, Heather G. Stockwell, Anna R. Giuliano

Research output: Contribution to journalArticle

Abstract

In women, naturally induced anti-human papilloma virus (HPV) serum antibodies are a likely marker of host immune protection against subsequent HPV acquisition and progression to precancerous lesions and cancers. However, it is unclear whether the same is the case in men. In this study, we assessed the risk of incident genital infection and 6-month persistent genital infection with HPV16 in relation to baseline serostatus in a cohort of 2,187 men over a 48-month period. Genital swabs were collected every 6 months and tested for HPV presence. Incidence proportions by serostatus were calculated at each study visit to examine whether potential immune protection attenuated over time. Overall, incidence proportions did not differ statistically between baseline seropositive and seronegative men at any study visit or over the follow-up period. The risk of incident and 6-month persistent infection was not associated with baseline serostatus or baseline serum antibody levels in the cohort. Our findings suggest that baseline HPV seropositivity in men is not associated with reduced risk of subsequent HPV16 acquisition. Thus, prevalent serum antibodies induced by prior infection may not be a suitable marker for subsequent immune protection against genital HPV16 acquisition in men.

Original languageEnglish (US)
Pages (from-to)676-685
Number of pages10
JournalCancer Research
Volume72
Issue number3
DOIs
StatePublished - Feb 1 2012

Fingerprint

Papillomaviridae
Biomarkers
Antibodies
Serum
Infection
Incidence
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. / Lu, Beibei; Viscidi, Raphael P; Wu, Yougui; Lee, Ji Hyun; Nyitray, Alan G.; Villa, Luisa L.; Lazcano-Ponce, Eduardo; Carvalho Da Silva, Roberto J.; Baggio, Maria Luiza; Quiterio, Manuel; Salmeron, Jorge; Smith, Danelle C.; Abrahamsen, Martha E.; Papenfuss, Mary R.; Stockwell, Heather G.; Giuliano, Anna R.

In: Cancer Research, Vol. 72, No. 3, 01.02.2012, p. 676-685.

Research output: Contribution to journalArticle

Lu, B, Viscidi, RP, Wu, Y, Lee, JH, Nyitray, AG, Villa, LL, Lazcano-Ponce, E, Carvalho Da Silva, RJ, Baggio, ML, Quiterio, M, Salmeron, J, Smith, DC, Abrahamsen, ME, Papenfuss, MR, Stockwell, HG & Giuliano, AR 2012, 'Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men', Cancer Research, vol. 72, no. 3, pp. 676-685. https://doi.org/10.1158/0008-5472.CAN-11-0751
Lu, Beibei ; Viscidi, Raphael P ; Wu, Yougui ; Lee, Ji Hyun ; Nyitray, Alan G. ; Villa, Luisa L. ; Lazcano-Ponce, Eduardo ; Carvalho Da Silva, Roberto J. ; Baggio, Maria Luiza ; Quiterio, Manuel ; Salmeron, Jorge ; Smith, Danelle C. ; Abrahamsen, Martha E. ; Papenfuss, Mary R. ; Stockwell, Heather G. ; Giuliano, Anna R. / Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. In: Cancer Research. 2012 ; Vol. 72, No. 3. pp. 676-685.
@article{a941723e8271422e9d3c2a4dd4a26601,
title = "Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men",
abstract = "In women, naturally induced anti-human papilloma virus (HPV) serum antibodies are a likely marker of host immune protection against subsequent HPV acquisition and progression to precancerous lesions and cancers. However, it is unclear whether the same is the case in men. In this study, we assessed the risk of incident genital infection and 6-month persistent genital infection with HPV16 in relation to baseline serostatus in a cohort of 2,187 men over a 48-month period. Genital swabs were collected every 6 months and tested for HPV presence. Incidence proportions by serostatus were calculated at each study visit to examine whether potential immune protection attenuated over time. Overall, incidence proportions did not differ statistically between baseline seropositive and seronegative men at any study visit or over the follow-up period. The risk of incident and 6-month persistent infection was not associated with baseline serostatus or baseline serum antibody levels in the cohort. Our findings suggest that baseline HPV seropositivity in men is not associated with reduced risk of subsequent HPV16 acquisition. Thus, prevalent serum antibodies induced by prior infection may not be a suitable marker for subsequent immune protection against genital HPV16 acquisition in men.",
author = "Beibei Lu and Viscidi, {Raphael P} and Yougui Wu and Lee, {Ji Hyun} and Nyitray, {Alan G.} and Villa, {Luisa L.} and Eduardo Lazcano-Ponce and {Carvalho Da Silva}, {Roberto J.} and Baggio, {Maria Luiza} and Manuel Quiterio and Jorge Salmeron and Smith, {Danelle C.} and Abrahamsen, {Martha E.} and Papenfuss, {Mary R.} and Stockwell, {Heather G.} and Giuliano, {Anna R.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-11-0751",
language = "English (US)",
volume = "72",
pages = "676--685",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men

AU - Lu, Beibei

AU - Viscidi, Raphael P

AU - Wu, Yougui

AU - Lee, Ji Hyun

AU - Nyitray, Alan G.

AU - Villa, Luisa L.

AU - Lazcano-Ponce, Eduardo

AU - Carvalho Da Silva, Roberto J.

AU - Baggio, Maria Luiza

AU - Quiterio, Manuel

AU - Salmeron, Jorge

AU - Smith, Danelle C.

AU - Abrahamsen, Martha E.

AU - Papenfuss, Mary R.

AU - Stockwell, Heather G.

AU - Giuliano, Anna R.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - In women, naturally induced anti-human papilloma virus (HPV) serum antibodies are a likely marker of host immune protection against subsequent HPV acquisition and progression to precancerous lesions and cancers. However, it is unclear whether the same is the case in men. In this study, we assessed the risk of incident genital infection and 6-month persistent genital infection with HPV16 in relation to baseline serostatus in a cohort of 2,187 men over a 48-month period. Genital swabs were collected every 6 months and tested for HPV presence. Incidence proportions by serostatus were calculated at each study visit to examine whether potential immune protection attenuated over time. Overall, incidence proportions did not differ statistically between baseline seropositive and seronegative men at any study visit or over the follow-up period. The risk of incident and 6-month persistent infection was not associated with baseline serostatus or baseline serum antibody levels in the cohort. Our findings suggest that baseline HPV seropositivity in men is not associated with reduced risk of subsequent HPV16 acquisition. Thus, prevalent serum antibodies induced by prior infection may not be a suitable marker for subsequent immune protection against genital HPV16 acquisition in men.

AB - In women, naturally induced anti-human papilloma virus (HPV) serum antibodies are a likely marker of host immune protection against subsequent HPV acquisition and progression to precancerous lesions and cancers. However, it is unclear whether the same is the case in men. In this study, we assessed the risk of incident genital infection and 6-month persistent genital infection with HPV16 in relation to baseline serostatus in a cohort of 2,187 men over a 48-month period. Genital swabs were collected every 6 months and tested for HPV presence. Incidence proportions by serostatus were calculated at each study visit to examine whether potential immune protection attenuated over time. Overall, incidence proportions did not differ statistically between baseline seropositive and seronegative men at any study visit or over the follow-up period. The risk of incident and 6-month persistent infection was not associated with baseline serostatus or baseline serum antibody levels in the cohort. Our findings suggest that baseline HPV seropositivity in men is not associated with reduced risk of subsequent HPV16 acquisition. Thus, prevalent serum antibodies induced by prior infection may not be a suitable marker for subsequent immune protection against genital HPV16 acquisition in men.

UR - http://www.scopus.com/inward/record.url?scp=84863072028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863072028&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-0751

DO - 10.1158/0008-5472.CAN-11-0751

M3 - Article

C2 - 22123925

AN - SCOPUS:84863072028

VL - 72

SP - 676

EP - 685

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -